Bouvel Investment Partners LLC Sells 1,998 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Bouvel Investment Partners LLC lowered its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 4.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,882 shares of the company’s stock after selling 1,998 shares during the quarter. Bouvel Investment Partners LLC’s holdings in Adaptive Biotechnologies were worth $225,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. JTC Employer Solutions Trustee Ltd acquired a new stake in Adaptive Biotechnologies during the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Adaptive Biotechnologies during the third quarter worth $34,000. Rothschild Investment LLC acquired a new stake in shares of Adaptive Biotechnologies during the second quarter worth $36,000. MQS Management LLC bought a new stake in Adaptive Biotechnologies in the 2nd quarter valued at $36,000. Finally, Pinnacle Wealth Planning Services Inc. acquired a new position in Adaptive Biotechnologies in the 1st quarter worth $46,000. Institutional investors own 99.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ADPT shares. Piper Sandler lifted their price target on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research note on Monday. JPMorgan Chase & Co. lifted their target price on Adaptive Biotechnologies from $5.00 to $6.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Finally, BTIG Research boosted their target price on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ:ADPT opened at $5.85 on Thursday. The company’s 50-day moving average price is $4.91 and its two-hundred day moving average price is $4.22. Adaptive Biotechnologies Co. has a one year low of $2.28 and a one year high of $6.70. The stock has a market capitalization of $863.34 million, a PE ratio of -4.37 and a beta of 1.45.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.